Herbal Medicine By China’s Tasly First TCM In Western Trials
This article was originally published in PharmAsia News
Executive Summary
Traditional Chinese medicine appears to be gaining greater acceptance in the Western, although there is widespread agreement on a need for standardization. China's Tasly Pharmaceutical has submitted an herbal drug, danshen, already available in much of Africa for treating a variety of diseases, is undergoing clinical trials in the European Union and in the United States where the FDA approved it as the first TCM for testing. The lack of scientific proof for the effectiveness of herbal treatments, some used in other countries for hundreds of years, has stymied their acceptance by Western drug makers and nations. U.S. and Chinese agree globalization will come only after TCM compounds are subjected to standardization. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.